started · updated
Siset Congress: Advances in Hemophilia and Thrombosis Treatments
At the XXIX National Congress of the Italian Society for the Study of Hemostasis and Thrombosis (Siset) in Rome, medical experts highlighted significant advancements in personalized treatments for blood disorders.
Flora Peyvandi, a professor at the University of Milan, noted that bispecific drugs have transformed the lives of hemophilia patients, particularly those with inhibitors. These bioengineered molecules aim to activate coagulation rather than simply infusing missing factors, allowing for subcutaneous injections at much wider intervals. Additionally, gene therapy has shown promising results for hemophilia B, maintaining factor IX levels for several years after a single infusion.
Giancarlo Castaman, president of Siset, emphasized a shift toward tailored therapies that prioritize a patient's quality of life and lifestyle over purely clinical data. He noted that while prophylaxis has nearly eliminated bleeding risks, research is now focusing on minimizing treatment burden and managing pain.
Regarding elderly patients, hematologist Alberto Tosetto stressed the necessity of a careful risk-benefit balance when using anticoagulants. He advised that clinicians must identify individual hemorrhage risks and consider patient preferences and the availability of caregivers to ensure correct therapy usage.
Entities
Alberto Tosetto · Flora Peyvandi · Giancarlo Castaman · Paolo Gresele · Rome · Siset · University of Milan · University of Perugia
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] Congenital platelet disorders are more frequent than Hemophilia A and Von Willebrand disease.
- [● 3 SOURCES] A new bispecific monoclonal antibody is in advanced clinical trials.
- [● 3 SOURCES] The XXIX National Congress of Siset was held in Rome.
- [● 3 SOURCES] Anti-angiogenic therapies may provide advantages for patients with gastrointestinal hemorrhaging related to platelet disorders.
- [○ 1 SOURCE] Anticoagulant therapy for venous thromboembolism typically lasts 6 to 12 months.
- [● 2 SOURCES] Hemorrhagic risk in hemophilia is nearly eliminated due to prophylaxis.
- [● 2 SOURCES] Researchers aim to develop curative gene therapies for hemophilia that are applicable from early life.
- [● 2 SOURCES] New medications allow for personalized treatment profiles for hemophilia and thrombosis patients.
- [○ 1 SOURCE] Elderly patients require a careful balance between hemorrhagic risk and the benefits of anticoagulants.
- [● 2 SOURCES] Treatment focus for hemophilia is shifting toward lifestyle, pain management, and treatment burden.